RT @EricTopol: The more potent and bespoke immunotherapy vs cancer, the better. Today's example is a neoantigen vaccine vs melanoma.https:/….

RT @Cancer_Cell: Online Now: KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung ca….

Excited to lead efforts across discovery and clinical strategy to bring therapies for patients with rare cancers where the need is great and the impact can be life-changing. It’s an honor to join a team so dedicated to advancing science and making a real difference for patients.

I'm happy to share that I’ve started a new position as Executive Director, Head of Rare Cancer Discovery @AstraZeneca and @AlexionPharmaUS . Looking forward to what’s ahead!.

RT @ImmunityCP: Online now: Niche-specific therapeutic targeting of myeloid cells in the central nervous system

RT @gminniti2012: Good update of recommendation for LGG management in the era of vorssidenib. More trials in progress.@EANOassociation .@EO….

RT @DrChoueiri: “I see death’s random strikes, who it strikes, it slays and who it misses will to old age live out his days”—Zuhayr bin Abī….

Brain tumors don't discriminate—they impact people of all ages, backgrounds, and walks of life. At #AstraZeneca and #Alexion, we are deeply committed to advancing science and innovation in the fight against brain tumors.

May is Brain Tumor Awareness Month. Every year, thousands of individuals are affected by brain tumors. This month, we honor the strength of patients, the dedication of caregivers, and the tireless work of medical professionals and researchers fighting for a cure.

A groundbreaking case study that may redefine GBM immunotherapy! The first report on upfront neoadjuvant administration of #immunecheckpoint inhibitors in #GBM followed by tumor resection. Patient remains recurrence-free after 17months.

RT @AlexionPharmaUS: We proudly stand with the rare disease community, highlighting their resilience and inspiring our continued efforts to….

On #RareDiseaseDay, we @AlexionPharmaUS and @AstraZeneca AstraZeneca renew our commitment to those impacted by #raredisease, especially #rarecancer. Together, we’re making a difference. 💙.#RareCancer #RareDisease #HopeInResearch #PatientCentric #AstraZeneca #Alexion

I had the honor of chairing the #GBM Summit in Boston where experts from patient advocacy, academia, biotech and pharma were brought together to explore advancements in GBM research and treatment. @AstraZeneca @AlexionPharmaUS #rarecancer #waragainstGBM

Ultrasound neurotechnologies moving quickly to the clinic, a nice review article on the use of ultrasound in different applications highlighting low-intensity focused ultrasound to open the BBB to enhance delivery of therapeutics to the brain.

RT @NatRevDrugDisc: For readers interested in bispecific antibodies as cancer therapies, here's a comprehensive review ..

On #WorldCancerDay, we honor the courage of those battling cancer and reaffirm our dedication @AstraZeneca and @AlexionPharma to drive progress in rare cancer to give hope to patients who need it most. #RareCancers #CancerCare #Glioblastoma #DiffuseMidlineGliomas #DIPG #Sarcoma

RT @NatureRevCancer: #REVIEW 🚨. Hanahan, Michielin & Pittet discuss how, nearly all cell types in the tumour microenvironment can be progr….

Looking forward co-chairing the 6th Annual Glioblastoma Drug Development Summit. Pharma experts, Neurosurgeons, Neurooncologists and importantly patients and patients advocates come together to discuss the latest breakthroughs in tackling glioblastoma.

Cancer statistics 2025 are in with alarming results: cancer impacting younger, more female, and racial disparities in mortality persist.

RT @NatureRevCancer: NEW content online! Metabolic interplays between the tumour and the host shape the tumour macroenvironment https://t.c….